CytomX's CX-2051, a PROBODY® EpCAM-targeted antibody-drug conjugate (ADC), showed a 28% confirmed response rate and 5.8-month ...

Leucid Bio has dosed the first patient in its Phase 1 AERIAL trial of LEU011, an NKG2D-targeting CAR-T therapy for solid ...

Noval ADC candidate ADRX-0706 received FDA Fast Track designation for advanced cervical cancer. Targeting Nectin-4 with a ...

Johnson & Johnson’s Oncology Care Index reveals 73% of oncologists see a gap between new cancer treatments and clinical ...

In a 286-patient Phase 2 trial, elraglusib combined with gemcitabine/nab-paclitaxel achieved a statistically significant ...

Phase III POTOMAC trial showed that adding Durvalumab (Imfinzi) to BCG induction and maintenance therapy significantly ...

The Phase III DESTINY-Breast11 trial showed Enhertu followed by THP significantly improved pathologic complete response (pCR) ...

For the first time, the FDA completed a generative AI-assisted scientific review pilot, cutting review tasks from days to ...

The phase II ROME trial demonstrated that personalized therapy guided by combined tissue and liquid biopsies significantly ...